ARTICLE | Clinical News
IPL576,092: Began Phase II Trial
January 2, 2001 8:00 AM UTC
Inflazyme Pharmaceuticals Ltd. (TSE:IZP), Richmond, B.C. Product: IPL576,092 Business: Autoimmune/Inflammation Therapeutic category: Cytokine production Target: Unknown Description: Oral compound deri...